Summit Therapeutics Inc.: operating expenses
Operating expenses for Summit Therapeutics Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Summit Therapeutics Inc. financial histories
What this measure means
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
Exact concept: us-gaap:OperatingExpenses. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-02-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 1,094,424,000 | USD | 2026-02-23 | 10-K · 0001599298-26-000015 |
| 2024-01-01 | 2024-12-31 | 225,998,000 | USD | 2026-02-23 | 10-K · 0001599298-26-000015 |
| 2023-01-01 | 2023-12-31 | 609,650,000 | USD | 2026-02-23 | 10-K · 0001599298-26-000015 |
| 2022-01-01 | 2022-12-31 | 87,210,000 | USD | 2025-02-24 | 10-K · 0001599298-25-000048 |
| 2021-01-01 | 2021-12-31 | 108,963,000 | USD | 2023-03-09 | 10-K · 0001599298-23-000034 |
| 2020-01-01 | 2020-12-31 | 73,365,000 | USD | 2022-12-21 | 10-K/A · 0001599298-22-000147 |
| 2019-02-01 | 2019-12-31 | 51,088,000 | USD | 2021-03-31 | 10-K · 0001599298-21-000011 |
| 2018-02-01 | 2019-01-31 | 74,307,000 | USD | 2021-03-31 | 10-K · 0001599298-21-000011 |
Related financial histories
- Summit Therapeutics Inc.: total assets
- Summit Therapeutics Inc.: total liabilities
- Summit Therapeutics Inc.: stockholders equity
- Summit Therapeutics Inc.: cash and cash equivalents
- Summit Therapeutics Inc.: net income or loss
- Summit Therapeutics Inc.: operating cash flow
- Summit Therapeutics Inc.: capital expenditure payments
- Summit Therapeutics Inc.: contract revenue excluding tax
- Summit Therapeutics Inc.: financing cash flow
- Summit Therapeutics Inc.: investing cash flow
- Summit Therapeutics Inc.: retained earnings or deficit
- Summit Therapeutics Inc.: basic weighted-average shares
- Summit Therapeutics Inc.: diluted weighted-average shares
- Summit Therapeutics Inc.: basic earnings per share
- Summit Therapeutics Inc.: diluted earnings per share
- Summit Therapeutics Inc.: income tax expense or benefit
- Summit Therapeutics Inc.: net property, plant and equipment
- Summit Therapeutics Inc.: share-based compensation expense
- Summit Therapeutics Inc.: operating income or loss
- Summit Therapeutics Inc.: current assets
- Summit Therapeutics Inc.: interest expense
- Summit Therapeutics Inc.: current liabilities
- Summit Therapeutics Inc.: current accounts payable
- Summit Therapeutics Inc.: goodwill carrying amount
- Summit Therapeutics Inc.: net finite-lived intangible assets
- Summit Therapeutics Inc.: net current accounts receivable
- Summit Therapeutics Inc.: research and development expense
Inspect the source
- Entity
- Summit Therapeutics Inc. / CIK 0001599298
- Captured
- 2026-09-20T09:25:07.920Z
- SEC response SHA-256
596f61ad9d5736983fe2b79f39f1ba867d5f55226d19f60db0e5d837be4c024e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001599298.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))